Zometapine was first synthesized in the 1970s by the pharmaceutical company Novartis. It was initially developed as a potential treatment for schizophrenia and other psychotic disorders. However, despite showing promise in early clinical trials, the drug was never marketed and is not currently approved for use in any country.
Zometapine acts primarily as a dopamine antagonist, blocking the action of the neurotransmitter dopamine in the brain. It also has significant serotonin antagonist activity, which may contribute to its antipsychotic effects. In addition, zometapine has been found to have anticholinergic properties, which can cause side effects such as dry mouth and blurred vision.
While zometapine is not currently approved for use in any country, it has been studied in clinical trials for the treatment of schizophrenia and other psychotic disorders. These studies have suggested that zometapine may be effective in reducing the symptoms of these conditions, although further research is needed to confirm these findings.
The most common side effects of zometapine are similar to those of other atypical antipsychotics and include drowsiness, dizziness, and weight gain. Due to its anticholinergic properties, zometapine can also cause dry mouth, blurred vision, and constipation. In rare cases, zometapine may cause serious side effects such as neuroleptic malignant syndrome or tardive dyskinesia.
